Combination therapy emerges as possible treatment for an aggressive form of kidney cancer
A genetic vulnerability in clear cell renal cell carcinoma, the most aggressive type of kidney cancer, may lend itself to a combination treatment strategy that causes the cancer cells to self-destruct, according to recent research published in the Proceedings of the National Academy of Sciences.
A groundbreaking study published in the Proceedings of the National Academy of Sciences reveals that a combination of belzutifan and a lab-made TRAIL protein could be a potent treatment for clear cell renal cell carcinoma, the most aggressive type of kidney cancer. Belzutifan, an FDA-approved drug, helps reduce HIF-2-alpha protein levels, which in turn lowers intracellular TRAIL and frees up death receptors on cancer cells.
These receptors are then exposed to the recombinant TRAIL, prompting the cells to undergo apoptosis, or programmed cell death. This novel approach bypasses resistance issues and offers a promising new avenue for treating clear cell renal cell carcinoma, according to researchers at the University of Notre Dame.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
